MedTrace Logo

Supportive Therapy in Androgen Deprivation Clinic in Improving Health Outcomes and Managing Side Effects in Patients With Prostate Cancer

NCT02168062 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 57

Last updated 2020-07-23

Study results available
· View outcomes & findings →

Summary

This pilot partially-randomized phase II trial studies how well Supportive Therapy in Androgen Deprivation (STAND) clinic works in improving health outcomes and managing side effects in patients with prostate cancer. Individualized counseling regarding exercise and dietary habits may help improve patient understanding, satisfaction, and overall lessen adverse impact on quality of life caused by androgen deprivation.

Conditions

  • Prostate Adenocarcinoma

Interventions

BEHAVIORAL

Behavioral Dietary Intervention

Receive individualized nutrition counseling

OTHER

Counseling

Receive individualized symptom management service counseling

OTHER

Educational Intervention

Review educational modules

BEHAVIORAL

Exercise Intervention

Receive individualized exercise counseling

DRUG

Goserelin Acetate

Given SC

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Leuprolide Acetate

Given SC or IM

OTHER

Quality-of-Life Assessment

Ancillary studies

DRUG

Triptorelin Pamoate

Given IM

Sponsors & Collaborators

Principal Investigators

  • Rahul Aggarwal, MD · University of California, San Francisco

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
CROSSOVER

Eligibility

Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-16
Primary Completion
2018-05-22
Completion
2018-05-22
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02168062 on ClinicalTrials.gov